Temozolomide and Bevacizumab Induction before Chemoradiotherapy in Patients with Bulky Glioblastoma and/or with Severe Neurological Impairment

Background.New approaches are needed for patients newly diagnosed with bulky glioblastoma (GB) and/or with severe neurological impairment that cannot benefit from first line temozolomide (TMZ)-based chemoradiotherapy. Bevacizumab (BEV), an antiangiogenic anti-VEGF-R monoclonal antibody, has a rapid...

Descripción completa

Detalles Bibliográficos
Autores principales: Darmon, Ilan, Morisse, Mony Chenda, Coutte, Alexandre, Blonski, Marie, Le Rhun, Emilie, Taillandier, Luc, Roufai, Diana Bello, Desenclos, Christine, Trudel, Stéphanie, Faivre, Jean-Christophe, Blanchard, Nicolas, Chauffert, Bruno, Boone, Mathieu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479247/
https://www.ncbi.nlm.nih.gov/pubmed/28638456
http://dx.doi.org/10.7150/jca.18339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479247/
https://www.ncbi.nlm.nih.gov/pubmed/28638456
http://dx.doi.org/10.7150/jca.18339

Ejemplares similares